Nothing Special   »   [go: up one dir, main page]

Sugaya et al., 2002 - Google Patents

Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy

Sugaya et al., 2002

View PDF
Document ID
12056446619038739785
Author
Sugaya M
Takenoyama M
Osaki T
Yasuda M
Nagashima A
Sugio K
Yasumoto K
Publication year
Publication venue
Chest

External Links

Snippet

Background Since lung cancer is the major cause of death not only in Japan but in many other industrialized countries, the development of new therapeutic modalities is quite important. In patients with melanoma, immunotherapy with some tumor antigens has been …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Similar Documents

Publication Publication Date Title
Sugaya et al. Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy
Wang et al. Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells
So et al. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer
López-Albaitero et al. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL
Baurain et al. High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene
Jäger et al. Clonal expansion of Melan A‐specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma‐associated peptides
US7404270B2 (en) Tumor antigen
Straetemans et al. TCR Gene Transfer: MAGE‐C2/HLA‐A2 and MAGE‐A3/HLA‐DP4 Epitopes as Melanoma‐Specific Immune Targets
Rodolfo et al. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen
JP2008109928A (en) Mage-a1 peptide presented by hla class ii molecule
Ma et al. Two new tumor‐specific antigenic peptides encoded by gene MAGE‐C2 and presented to cytolytic T lymphocytes by HLA‐A2
JP2004536590A (en) MAGE-A3 peptide presented by HLA class II molecule
CN112673018A (en) MR 1-restricted T cell receptor for cancer immunotherapy
Ikuta et al. A HER2/NEU‐derived peptide, a Kd‐restricted murine tumor rejection antigen, induces HER2‐specific HLA‐A2402‐restricted CD8+ cytotoxic T lymphocytes
Weynants et al. Derivation of tumor-specific cytolytic T-cell clones from two lung cancer patients with long survival
Tanna et al. Critical testing and parameters for consideration when manufacturing and evaluating tumor–associated antigen-specific T cells
Klyushnenkova et al. CD4 and CD8 T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis
Neumann et al. Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells
US20040033541A1 (en) MAGE-A4 antigenic peptides and uses thereof
Ciernik et al. Human lung cancer cells endogenously expressing mutant p53 process and present the mutant epitope and are lysed by mutant-specific cytotoxic T lymphocytes.
Hanagiri et al. Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1
JP2002531088A (en) Major rejection antigen
Godelaine et al. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44
Takenoyama et al. Autologous tumor‐specific cytotoxic T lymphocytes in a patient with lung adenocarcinoma: implications of the shared antigens expressed in HLA‐A24 lung cancer cells
Nagata et al. Identification of the HLA-Cw* 0702-restricted tumor-associated antigen recognized by a CTL clone from a lung cancer patient